Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease
Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease
This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Vural KAVUNCU, Prof. Dr.
- Phone Number: 90 505 777 43 06
- Email: vural.kavuncu@ksbu.edu.tr
Study Contact Backup
- Name: Meltem ÇOBAN, Dr.
- Phone Number: +90 544 284 42 58
- Email: meltem.368@hotmail.com
Study Locations
-
-
-
Kütahya, Turkey (Türkiye), 43020
- Kutahya Health Sciences University
-
Contact:
- Vural KAVUNCU, Prof. Dr.
- Phone Number: 1111 02742630043
- Email: vural.kavuncu@ksbu.edu.tr
-
Principal Investigator:
- Fatima YAMAN, Assoc. Prof
-
Principal Investigator:
- Meltem ÇOBAN, Dr.
-
Sub-Investigator:
- Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
-
Sub-Investigator:
- Mevlüt DEMİR, Assoc. Prof
-
Sub-Investigator:
- Cansu OZBAYER, Prof. Dr.
-
Sub-Investigator:
- Fatih KAR, Assoc. Prof.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stable coronary artery disease
- History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Referred and considered clinically eligible for a structured cardiac rehabilitation program
- Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
- Ability and willingness to participate in the study and complete the cardiac rehabilitation program
Exclusion Criteria:
- Symptoms or signs of myocardial ischemia
- Significant left ventricular outflow tract obstruction
- Ventricular arrhythmia
- Significant valvular heart disease
- Uncontrolled hypertension
- Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
- Active malignancy
- Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
- Body mass index greater than 35 kg/m²
- History of orthopedic surgery within the previous 6 months
- Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
- Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
- Known psychiatric disorder
- Presence of a permanent cardiac pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Personalized Cardiac Rehabilitation Group
Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program. |
Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in miRNA Expression Levels
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Peak Oxygen Uptake (VO₂max)
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Exercise Workload
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Six-Minute Walk Test Distance
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Resting Heart Rate
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Heart Rate
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Health-Related Quality of Life
Time Frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KSBÜ-CR-miRNA-
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.